Sanofi rules out major overhaul, weighs higher European prices under Trump deal

· Health · France · United States

Sanofi said Friday it is not planning "major" changes to its business or R&D pipeline, six months after Belén Garijo took over as chief executive, even as the patent cliff for its top-selling drug Dupixent looms. The French drugmaker is taking a different approach from peers on pricing, signaling it may seek higher European drug prices rather than withhold launches under President Donald Trump's pricing policies. Some of Europe's biggest drugmakers have warned that those policies could leave European patients waiting longer for new medicines. Sanofi's stance suggests it will pursue price increases in Europe instead of delaying market entry, a contrast that could influence how other companies respond to US-driven pricing pressure.

Why it matters：Sanofi's choice to push European prices rather than delay launches tests whether drugmakers can offset US pricing pressure without shortchanging other markets, a decision other companies may follow.

Key points

  • Sanofi said no "major" business or R&D overhaul is planned under CEO Belén Garijo.
  • The company may seek higher European prices rather than withhold launches.
  • Dupixent's patent cliff is the backdrop for the strategy.

Sources (original reporting)

More stories from this day